| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Wu,Yong-Lian | Chairman | 1.65% | |
| Huang,Rong-Yi | Director | 9.75% | Fubon Financial Holding Venture Capital Co., Ltd |
| ZHONG JIA CONSULTANT CO., LTD. | Director | 0.00% | |
| Li,Cong-Rong | Director | 5.70% | |
| Lin,Dong-He | Director | 0.00% | |
| Liu,Zhi-Hong | Independent Director | 0.00% | |
| Li,Lian-Zi | Independent Director | 0.00% | |
| Sun,Yi-Ming | Independent Director | 0.00% | |
| Zhou,Pei-Fen | Independent Director | 0.00% |
Change Company Name to Sunny Pharmtech Inc.
2024/07/29
Change Capital to 2,000,000,000
2023/07/06
Change Company Name to XIANGYI PHARMACEUTICAL CO., LTD. (FORMER NAME: TAIWAN AXA DEVELOPMENT PHARMACEUTICAL CO., LTD.)
2022/07/13
Change Capital to 1,600,000,000
2021/07/28
Change Capital to 1,500,000,000
2017/05/19
Change Capital to 1,000,000,000
2015/11/26
Change Capital to 250,000,000
2014/11/24
Change Company Name to Sunny Pharmtech Inc.
2014/09/04
Change Person in Charge to Wu,Yong-Lian
2012/04/10
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 233,556 | 428,827 | 359,585 |
| Operating cost | 117,642 | 143,301 | 152,878 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 115,914 | 285,526 | 206,707 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 115,914 | 285,526 | 206,707 |
| Operating expenses | 164,019 | 357,622 | 394,327 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -48,105 | -72,096 | -187,620 |
| Non-operating income and expenses | 8,816 | 8,776 | 17,380 |
| Net profit (loss) before tax | -39,289 | -63,320 | -170,240 |
| Income tax expense (benefits) | 0 | 0 | 0 |
| Net profit (loss) of ongoing business for the current period | -39,289 | -63,320 | -170,240 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -39,289 | -63,320 | -170,240 |
| Other comprehensive profit (loss), net | - | - | - |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -39,289 | -63,320 | -170,240 |
| Net profit (loss) attributable to owners of parent company | - | - | - |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | - | - | - |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | 0 | -1 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | - | - | - |
| Net cash inflows (outflows) from investing activities | - | - | - |
| Net cash inflow (outflow) from financing activities | - | - | - |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | - | - | - |
| Beginning balance of cash and cash equivalents | - | - | - |
| Ending balance of cash and cash equivalents | - | - | - |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 434,914 | 460,491 | 413,983 |
| Non-current asset | 1,230,387 | 1,251,872 | 1,215,631 |
| Total asset | 1,665,301 | 1,712,363 | 1,629,614 |
| Current liability | 134,367 | 111,827 | 280,246 |
| Non-current liability | 368,649 | 400,610 | 380,071 |
| Total liability | 503,016 | 512,437 | 660,317 |
| share capital | 1,487,552 | 1,486,568 | 1,385,250 |
| Equity - secruity token | - | - | - |
| capital reserve | 20,984 | 209,527 | 16,896 |
| retained earning | -346,251 | -496,169 | -432,849 |
| Other equity | - | - | - |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | - | - | - |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 1,162,285 | 1,199,926 | 969,297 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 30,000 | 131,800 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 7 | 8 | 7 |
